• Something wrong with this record ?

Phytocannabinoids and gingival inflammation: Preclinical findings and a placebo-controlled double-blind randomized clinical trial with cannabidiol

P. Jirasek, A. Jusku, J. Frankova, M. Urbankova, D. Diabelko, F. Ruzicka, B. Papouskova, K. Chytilova, J. Vrba, J. Havlasek, K. Langova, J. Storch, I. Voborna, V. Simanek, J. Vacek

. 2024 ; 59 (3) : 468-479. [pub] 20240205

Language English Country United States

Document type Journal Article, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc24013787

Grant support
RVO 61989592 UPOL
IGA_LF_2020_038 UPOL
IGA_LF_2022_025 UPOL
CZ.02.1.01/0.0/0.0/16_019/0000868 ENOCH

OBJECTIVE: The aim of this study was to: (1) evaluate the anti-inflammatory effects of cannabidiol (CBD) on primary cultures of human gingival fibroblasts (HGFs) and (2) to clinically monitor the effect of CBD in subjects with periodontitis. BACKGROUND: The use of phytocannabinoids is a new approach in the treatment of widely prevalent periodontal disease. MATERIALS AND METHODS: Cannabinoid receptors were analyzed by western blot and interleukin production detected using enzyme immunoassay. Activation of the Nrf2 pathway was studied via monitoring the mRNA level of heme oxygenase-1. Antimicrobial effects were determined by standard microdilution and 16S rRNA screening. In the clinical part, a placebo-control double-blind randomized study was conducted (56 days) in three groups (n = 90) using dental gel without CBD (group A) and with 1% (w/w) CBD (group B) and corresponding toothpaste (group A - no CBD, group B - with CBD) for home use to maintain oral health. Group C used dental gel containing 1% chlorhexidine digluconate (active comparator) and toothpaste without CBD. RESULTS: Human gingival fibroblasts were confirmed to express the cannabinoid receptor CB2. Lipopolysaccharide-induced cells exhibited increased production of pro-inflammatory IL-6 and IL-8, with deceasing levels upon exposure to CBD. CBD also exhibited antimicrobial activities against Porphyromonas gingivalis, with an MIC of 1.5 μg/mL. Activation of the Nrf2 pathway was also demonstrated. In the clinical part, statistically significant improvement was found for the gingival, gingival bleeding, and modified gingival indices between placebo group A and CBD group B after 56 days. CONCLUSIONS: Cannabidiol reduced inflammation and the growth of selected periodontal pathogenic bacteria. The clinical trial demonstrated a statistically significant improvement after CBD application. No adverse effects of CBD were reported by patients or observed upon clinical examination during the study. The results are a promising basis for a more comprehensive investigation of the application of non-psychotropic cannabinoids in dentistry.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013787
003      
CZ-PrNML
005      
20240905133455.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jre.13234 $2 doi
035    __
$a (PubMed)38311974
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jirasek, Petr $u Institute of Dentistry and Oral Sciences, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $u Institute of Dentistry and Oral Sciences, University Hospital Olomouc, Olomouc, Czech Republic $1 https://orcid.org/0000000161801627
245    10
$a Phytocannabinoids and gingival inflammation: Preclinical findings and a placebo-controlled double-blind randomized clinical trial with cannabidiol / $c P. Jirasek, A. Jusku, J. Frankova, M. Urbankova, D. Diabelko, F. Ruzicka, B. Papouskova, K. Chytilova, J. Vrba, J. Havlasek, K. Langova, J. Storch, I. Voborna, V. Simanek, J. Vacek
520    9_
$a OBJECTIVE: The aim of this study was to: (1) evaluate the anti-inflammatory effects of cannabidiol (CBD) on primary cultures of human gingival fibroblasts (HGFs) and (2) to clinically monitor the effect of CBD in subjects with periodontitis. BACKGROUND: The use of phytocannabinoids is a new approach in the treatment of widely prevalent periodontal disease. MATERIALS AND METHODS: Cannabinoid receptors were analyzed by western blot and interleukin production detected using enzyme immunoassay. Activation of the Nrf2 pathway was studied via monitoring the mRNA level of heme oxygenase-1. Antimicrobial effects were determined by standard microdilution and 16S rRNA screening. In the clinical part, a placebo-control double-blind randomized study was conducted (56 days) in three groups (n = 90) using dental gel without CBD (group A) and with 1% (w/w) CBD (group B) and corresponding toothpaste (group A - no CBD, group B - with CBD) for home use to maintain oral health. Group C used dental gel containing 1% chlorhexidine digluconate (active comparator) and toothpaste without CBD. RESULTS: Human gingival fibroblasts were confirmed to express the cannabinoid receptor CB2. Lipopolysaccharide-induced cells exhibited increased production of pro-inflammatory IL-6 and IL-8, with deceasing levels upon exposure to CBD. CBD also exhibited antimicrobial activities against Porphyromonas gingivalis, with an MIC of 1.5 μg/mL. Activation of the Nrf2 pathway was also demonstrated. In the clinical part, statistically significant improvement was found for the gingival, gingival bleeding, and modified gingival indices between placebo group A and CBD group B after 56 days. CONCLUSIONS: Cannabidiol reduced inflammation and the growth of selected periodontal pathogenic bacteria. The clinical trial demonstrated a statistically significant improvement after CBD application. No adverse effects of CBD were reported by patients or observed upon clinical examination during the study. The results are a promising basis for a more comprehensive investigation of the application of non-psychotropic cannabinoids in dentistry.
650    _2
$a lidé $7 D006801
650    12
$a kanabidiol $x farmakologie $x terapeutické užití $7 D002185
650    _2
$a dvojitá slepá metoda $7 D004311
650    12
$a fibroblasty $x účinky léků $7 D005347
650    _2
$a dospělí $7 D000328
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a gingiva $x účinky léků $7 D005881
650    12
$a gingivitida $x farmakoterapie $7 D005891
650    _2
$a lidé středního věku $7 D008875
650    _2
$a faktor 2 související s NF-E2 $7 D051267
650    _2
$a antiflogistika $x terapeutické užití $x farmakologie $7 D000893
650    _2
$a chlorhexidin $x terapeutické užití $x farmakologie $x analogy a deriváty $7 D002710
650    _2
$a kultivované buňky $7 D002478
650    _2
$a interleukin-6 $x analýza $7 D015850
650    _2
$a parodontitida $x farmakoterapie $7 D010518
650    _2
$a interleukin-8 $x účinky léků $7 D016209
650    _2
$a hemoxygenasa-1 $7 D051547
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Jusku, Alexandr $u Institute of Dentistry and Oral Sciences, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $u Institute of Dentistry and Oral Sciences, University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Frankova, Jana $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Urbankova, Marketa $u Department of Clinical and Molecular Pathology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Diabelko, Daniel $u Department of Microbiology, Faculty of Medicine of Masaryk University and St. Anne's University Hospital, Brno, Czech Republic
700    1_
$a Ruzicka, Filip $u Department of Microbiology, Faculty of Medicine of Masaryk University and St. Anne's University Hospital, Brno, Czech Republic
700    1_
$a Papouskova, Barbora $u Department of Analytical Chemistry, Faculty of Science, Palacky University, Olomouc, Czech Republic
700    1_
$a Chytilova, Karin $u Department of Oral and Maxillofacial Surgery, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Vrba, Jiri $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Havlasek, Jakub $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Langova, Katerina $u Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Olomouc, Czech Republic
700    1_
$a Storch, Jan $u Department of Advanced Materials and Organic Synthesis, Institute of Chemical Process Fundamentals of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Voborna, Iva $u Institute of Dentistry and Oral Sciences, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $u Institute of Dentistry and Oral Sciences, University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Simanek, Vilim $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Vacek, Jan $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $1 https://orcid.org/000000015490082X
773    0_
$w MED00002888 $t Journal of periodontal research $x 1600-0765 $g Roč. 59, č. 3 (2024), s. 468-479
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38311974 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133449 $b ABA008
999    __
$a ok $b bmc $g 2143539 $s 1225653
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 59 $c 3 $d 468-479 $e 20240205 $i 1600-0765 $m Journal of periodontal research $n J Periodontal Res $x MED00002888
GRA    __
$a RVO 61989592 $p UPOL
GRA    __
$a IGA_LF_2020_038 $p UPOL
GRA    __
$a IGA_LF_2022_025 $p UPOL
GRA    __
$a CZ.02.1.01/0.0/0.0/16_019/0000868 $p ENOCH
LZP    __
$a Pubmed-20240725
Back

Find record

Citation metrics

Archiving options